Biochip technology of SHG139S showed several miRNA and lncRNA were differently expressed in SHG139 and SHG139S.



Biochip technology
The new glioma cell line SHG-139 was established and its phenotype, tumorigenicity, pathological characteristics, derived stem cells SHG139S were studied.


 Immunohistochemistry was used to assess expressions in the patient and mouse tumor tissues, SHG-139 and SHG-139S.  Primary SHG-139 culture was performed, cell proliferation, cell cycle and genetic characteristics were assessed.  SHG-139 proliferated significantly within 24h; its total number of chromosomes was 68; ratios of SHG-139 and SHG-139S cells in G1 phase were highest.  SHG-139 cells were positive for A2B5, GalC (Galactocerebrosides), GFAP, S-100 and Vimentin, while SHG-139S cells were positive for A2B5, Nestin, and NG2 (Neuron-glia antigen2), and negative for Vimentin and IDHR132H (Isocitrate dehydrogenase); cells rarely stained for CD133 (Cluster of differentiation133).  SHG-139 intracranial xenografts expressed GFAP, but no overt oligodendroglioma was observed.  In SHG-139S xenografts, GFAP and S-100 were expressed, while CD133 was not detected; a few A2B5(+) cells were found at tumor edges, and typical oligodendroglioma were obtained.  In addition, SHG-139S xenograft tumors were more aggressive than those of SHG-139.  SHG-139 was an astroglioma cell line which yielded stem cells SHG-139S.  SHG-139S cells constituted an A2B5(+)/CD133(-) GSC subgroup.
SHG-139